TY - JOUR
T1 - SCORE2 Report 17
T2 - Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion
AU - for the SCORE2 Investigator Group
AU - Scott, Ingrid U.
AU - Oden, Neal L.
AU - VanVeldhuisen, Paul C.
AU - Ip, Michael S.
AU - Blodi, Barbara A.
N1 - Funding Information:
Neal L. Oden, Ph.D.: work supported by grant 1U10EY023529 from the National Eye Institute of the National Institutes of Health. Paul C. VanVeldhuisen, Ph.D.: work supported by grant 1U10EY023529 from the National Eye Institute of the National Institutes of Health. Ingrid U. Scott, M.D., M.P.H.: serves as Principal Investigator and Chair of SCORE2, which is funded by the National Eye Institute, has served as a consultant for Regeneron (Tarrytown, NJ), and has served on the Data and Safety Monitoring Committee of clinical trials sponsored by Novartis (Basel, Switzerland). Barbara A. Blodi, M.D.: No financial disclosures. Michael S. Ip, M.D.: Dr. Ip is a consultant for the following: Novartis (Basel, Switzerland), Genentech (South San Francisco, CA), Allergan (Irvine, CA), Regeneron (Tarrytown, NJ), RegenexBio (Rockville, MD), Apellis (Waltham, MA), Aerie Pharmaceuticals (Durham, NC), Alimera Sciences (Alpharetta, GA), Amgen (Thousand Oaks, CA), Cell Lineage Therapeutics (Carlsbad, CA), Clearside Biomedical (Alpharetta, GA).
Funding Information:
Supported by the National Eye Institute (National Institutes of Health, Department of Health and Human Services) grants U10EY023529, U10EY023533, and U10EY023521. Support also provided in part by Regeneron, Inc and Allergan, Inc through donation of investigational drug. This work was supported in part by an unrestricted grant from Research to Prevent Blindness, Inc. to the University of Wisconsin Madison Department of Ophthalmology and Visual Sciences and to the Jules Stein Eye Institute and Doheny Eye Institute, Department of Ophthalmology at the University of California Los Angeles, CA.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/5
Y1 - 2022/5
N2 - Purpose: To evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab. Methods: Post hoc analysis of 362 patients with ME secondary to CRVO or HRVO initially randomized to six monthly intravitreal injections of aflibercept or bevacizumab. Three spectral domain optical coherence tomography (SD-OCT) central subfield thickness (CST) fluctuation measures were investigated over Months 1–12: standard deviation (SD), number of turning points (T) for each participant, and a measure denoted as Zigzag reflecting the magnitude of alternating ups and downs in a participant’s CST. Main outcome measure is Month 12 visual acuity letter score (VALS). Results: More fluctuations occurred in eyes randomized to bevacizumab than aflibercept: SD (59.98 vs 32.12; p < 0.0001), T (4.03 vs 3.53; p = 0.02) and Zigzag (24.91 vs 11.60; p = 0.0003). Month 12 VALS is significantly lower for the 4th (highest) quartile of the CST fluctuation measure than for the 1st (lowest) quartile for both SD (mean difference in VALS of 7.87; 95% confidence interval: 3.03, 12.70) and Zigzag (mean difference in VALS of 5.11; 95% confidence interval: 0.29, 9.93). SD and Zigzag quartiles were no longer significantly different after Month 1 VALS was added to the regression analysis. Conclusions: Greater CST fluctuation as assessed by SD and Zigzag was negatively associated with Month 12 VALS. However, early post-treatment VALS is a stronger predictor of VALS outcomes than the CST fluctuation measures.
AB - Purpose: To evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab. Methods: Post hoc analysis of 362 patients with ME secondary to CRVO or HRVO initially randomized to six monthly intravitreal injections of aflibercept or bevacizumab. Three spectral domain optical coherence tomography (SD-OCT) central subfield thickness (CST) fluctuation measures were investigated over Months 1–12: standard deviation (SD), number of turning points (T) for each participant, and a measure denoted as Zigzag reflecting the magnitude of alternating ups and downs in a participant’s CST. Main outcome measure is Month 12 visual acuity letter score (VALS). Results: More fluctuations occurred in eyes randomized to bevacizumab than aflibercept: SD (59.98 vs 32.12; p < 0.0001), T (4.03 vs 3.53; p = 0.02) and Zigzag (24.91 vs 11.60; p = 0.0003). Month 12 VALS is significantly lower for the 4th (highest) quartile of the CST fluctuation measure than for the 1st (lowest) quartile for both SD (mean difference in VALS of 7.87; 95% confidence interval: 3.03, 12.70) and Zigzag (mean difference in VALS of 5.11; 95% confidence interval: 0.29, 9.93). SD and Zigzag quartiles were no longer significantly different after Month 1 VALS was added to the regression analysis. Conclusions: Greater CST fluctuation as assessed by SD and Zigzag was negatively associated with Month 12 VALS. However, early post-treatment VALS is a stronger predictor of VALS outcomes than the CST fluctuation measures.
UR - http://www.scopus.com/inward/record.url?scp=85120173859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120173859&partnerID=8YFLogxK
U2 - 10.1007/s00417-021-05494-5
DO - 10.1007/s00417-021-05494-5
M3 - Article
C2 - 34842984
AN - SCOPUS:85120173859
SN - 0065-6100
VL - 260
SP - 1491
EP - 1500
JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie
JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie
IS - 5
ER -